Bibliography
- COTTER PD, HILL C, ROSS PR: Bacterial lantibiotics: strategies to improve therapeutic potential. Curr. Prot. Pept. Sci. (2005) 6(1):61-75.
- CHATTERJEE C, PAUL M, XIE L, VAN DER DONK WA: Biosynthesis and mode of action of lantibiotics. Chem. Rev. (2005) 105(2):633-683.
- BROTZ H, BIERBAUM G, LEOPOLD K, REYNOLDS PE, SAHL HG: The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. (1998) 42(1):154-160.
- WIEDEMANN I, BOTTIGER T, BONELLI RR et al.: The mode of action of the lantibiotic lacticin 3147 – a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. (2006) 61(2):285-296.
- GOLDSTEIN BP, WEI J, GREENBERG K, NOVICK R: Activity of nisin against Streptococcus pneumoniae in vitro and in a mouse infection model. J. Antimicrob. Chemother. (1998) 42:277-278.
- HILLMAN JD, NOVAK J, SAGURA E et al.: Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect. Immun. (1998) 6(6):2743-2749.
- EKKELENKAMP MB, HANSSEN M, HSU ST et al.: Isolation and structural characterisation of epilancin 15X, a novel lantibiotic from a clinical strain of Staphylococcus epidermidis. FEBS Lett. (2005) 579:1917-1922.
- VAN DEN KAMP M, VAN DEN HOOVEN HW, KONINGS RN et al.: Elucidation of the primary structure of the lantibiotic epilancin K7 from Staphylococcus epidermidis K7. Cloning and characterisation of the epilancin-K7- encoding gene and NMR analysis of mature epilancin K7. Eur. J. Biochem. (1995) 230(2):587-600.
- ROSS KF, RONSON CW, TAGG JR: Isolation and characterisation of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl. Env. Microbiol. (1993) 59(7):2014-2021.
- PRIDMORE D, REKHIF N, PITTET AC, SURL B, MOLLET B: Variacin, a new lanthionine-containing bacteriocin produced by Micrococcus varians: comparison to lacticin 481 of Lactococcus lactis. Appl. Env. Microbiol. (1996) 62(5):1799-1802.
- COTTER PD, DEEGAN LH, LAWTON EM et al.: Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol. Microbiol. (2006) 62(3):735-747.
- NIU WW, NEU HC: Activity of mersacidin, a novel peptide, compared to that of vancomycin, teicoplanin and daptomycin. Antimicrob. Agents Chemother. (1991) 35(5):998-1000.
- CHATTERJEE S, CHATTERJEE DK, RANI RH et al.: Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiotics (1992) 45(6):839-845.
- KRUSZEWSKA D, SAHL HG, BIERBAUM G, PAG U, HYNES SO, LJUNGH A: Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. (2004) 54:648-653.
- ZEITLIN PL, GUGGINO WB, MOLINA L: Activation by the nonadecapeptide 2622U90 (duramycin) of chloride secretion in healthy volunteers and patients with cystic fibrosis. Paediatr. Pulmonol. 17(Suppl.):277.
Patents
- VICURON PHARMACEUTICALS: EP1646646 (2006).
- UNIVERSITY OF FLORIDA: US7067125 (2006).
- UNIVERSITY OF UTRECHT: EP1664101 (2005).
- UNIVERSITY OF OTAGO; BLIS TECHNOLOGIES: US6773912 (2004).
- NOVACTA BIOSYSTEMS: WO2005093069 (2005).
- VICURON PHARMACEUTICALS: EP1481986 (2004).
- INSTITUTE OF FOOD RESEARCH: WO2006111743 (2006).
- UNIVERSITY OF ILLINOIS: US2005/0164339 (2005).
- APPLIED NANOSYSTEMS: WO2006062398 (2006).
- MOLICHEM MEDICINES: WO2005115432 (2005).